Boehringer Ingelheim and OSE Immunotherapeutics Broaden Partnership

Boehringer Ingelheim and OSE Immunotherapeutics SA (OSE), a clinical-stage biotechnology firm, recently announced the expansion of their collaborative efforts. The enhanced partnership will introduce two new co-development initiatives focused on pioneering treatments for oncology and cardiorenal metabolic (CRM) diseases, augmenting their existing anti-SIRPα immuno-oncology project.

The first initiative aims to broaden the therapeutic scope of the assets from their current collaboration to include a wider patient demographic. The second initiative pertains to the acquisition and development of new assets, specifically the anti-SIRPα cancer immunotherapy compounds BI 765063 and BI 770371. These compounds, now in Phase I clinical trials for advanced solid tumors, will also be developed for CRM diseases, highlighting a dual-focus approach in their application.

In addition, the companies will embark on a new clinical-stage project leveraging OSE's proprietary cisMab anti-PD-1/cytokine platform, designed for immune cell activation therapy. This platform holds promise for enriching Boehringer Ingelheim's collection of innovative immune-modulatory oncology treatments.

This collaboration extension is a significant step for Boehringer Ingelheim, reinforcing its product pipeline and showcasing its steadfast commitment to discovering and developing new treatments to meet unaddressed patient needs, particularly in oncology and CRM diseases.

According to the agreement, OSE Immunotherapeutics will receive an initial payment of €13.5 million, with potential short-term milestone payments amounting to €17.5 million for the new clinical-stage cisMab anti-PD-1/cytokine platform asset. For the two active anti-SIRPα programs, BI 765063 and BI 770371, both parties have agreed to a partial buy-out, with Boehringer Ingelheim paying €25.3 million upfront.

This expanded collaboration highlights the shared dedication of Boehringer Ingelheim and OSE Immunotherapeutics to advancing pioneering treatments and tackling significant unmet medical needs in oncology and CRM diseases, which impact the lives of over a billion people worldwide.